bims-polgdi Biomed News
on POLG disease
Issue of 2026–11–01
thirty-two papers selected by
Luca Bolliger, lxBio



  1. Biochim Biophys Acta Mol Cell Res. 2026 Oct 24. pii: S0167-4889(26)00140-0. [Epub ahead of print] 120241
      Replication of the mitochondrial genome is essential to sustain cellular energy conversion, and defects in this process cause severe, progressive mitochondrial diseases that have long lacked curative treatment. This is now beginning to change: mechanistic insight into the replication machinery has started to translate into therapy, with the first disease-modifying treatment recently approved and others entering clinical evaluation. Here we review the molecular mechanisms of mitochondrial DNA replication, with emphasis on replication initiation, deletion formation, and replication completion, and discuss how insights into these processes are opening new therapeutic possibilities for treating mitochondrial disease.
    Keywords:  DNA replication; Deletion formation; Mitochondrial disease; POLG; Treatment
    DOI:  https://doi.org/10.1016/j.bbamcr.2026.120241
  2. Genes (Basel). 2026 Sep 22. pii: 1165. [Epub ahead of print]17(10):
      Mitochondrial genetic diseases arise from variants in mitochondrial DNA (mtDNA) or nuclear genes required for mitochondrial function. Although many involve several organs, the predominant clinical manifestations may be confined to particular organs. Experimental models are used to investigate variant pathogenicity, organ vulnerability, disease progression, therapeutic response, and safety. We discuss how to select animal models and other experimental systems for specific research questions. We focus on genetically engineered mice (constitutive knockout, knock-in/humanized, conditional/tissue-specific, inducible, and heteroplasmic mtDNA models) and consider when yeast, worms, flies, zebrafish, rats, large animals, companion animals, and human in vitro models can complement or replace particular animal experiments. We define deep phenotyping by five minimum characteristics: longitudinal assessment across defined disease stages; prespecified relationships among molecular, mitochondrial, organ, and whole-animal measurements; integration of repeated and terminal endpoints; alignment with patient-relevant disease stages; and separation of primary from exploratory outcomes. Model selection depends on the experimental objective and the evidence needed to address it. We also propose a multidomain framework that distinguishes target engagement, molecular correction, downstream pharmacodynamic responses, organ function, and whole-animal or patient-relevant benefit without assuming that effective treatments must improve every domain sequentially. We also discuss reporting practices, the 3Rs (Replacement, Reduction, and Refinement), and the implications of mtDNA editing, iPSC-derived systems, organoids, and automated phenotyping for study design.
    Keywords:  3Rs; animal model; deep phenotyping; heteroplasmy; mitochondrial disease; mouse model; mtDNA editing; preclinical research; reproducibility; translational research
    DOI:  https://doi.org/10.3390/genes17101165
  3. Sci Adv. 2026 Oct 30. 12(44): eaeg5364
      Cells exhibit innate reparative communication, enabling the exchange of bioactive molecules and, in some cases, entire organelles. Harnessing this endogenous process of intercellular organelle transfer represents an emerging therapeutic paradigm for restoring cellular function in diseases driven by organelle dysfunction. Mitochondrial transfer has gained prominence for its ability to restore bioenergetic capacity, mitigate oxidative stress, and rescue metabolic function in cells with impaired mitochondrial activity. Given that genetic or acquired defects in mitochondrial function are associated with diverse pathologies, including neurodegeneration, cardiovascular diseases, metabolic disorders, skeletal muscle defects, immune dysregulation, and age-associated decline, mitochondrial transfer offers broad therapeutic potential. Mitochondrial transfer seeks to deliver functional mitochondria to injured cells to reestablish metabolic competence. However, insufficient organelle trafficking and limited control over transfer dynamics remain critical barriers to clinical translation. Recent biotechnological developments aimed at enhancing donor-recipient connectivity, increasing mitochondrial availability, and modulating transfer machinery have begun to address some of these key challenges. This review highlights recent advances in mitochondrial transfer bioengineering, emerging therapeutic applications, and key challenges that must be resolved to enable clinical deployment.
    DOI:  https://doi.org/10.1126/sciadv.aeg5364
  4. Life (Basel). 2026 Sep 23. pii: 1590. [Epub ahead of print]16(10):
      Mitochondrial DNA (mtDNA) variation has traditionally been investigated in the context of human evolution and rare mitochondrial diseases; however, growing evidence suggests that it may also contribute to susceptibility to common metabolic disorders. This review integrates current knowledge of mitochondrial biology, mtDNA genetics, heteroplasmy, and the global distribution of mitochondrial haplogroups to examine their roles in health and disease. In this narrative review, we synthesized English-language studies identified through PubMed, Scopus, and Web of Science from January 1988 to May 2026, prioritizing evidence according to relevance, scientific contribution, recency, and historical significance. We summarize evidence showing how pathogenic variants (PVs) in mtDNA genes impair oxidative phosphorylation (OXPHOS), increase reactive oxygen species (ROS) production, and disrupt cellular bioenergetics, thereby contributing to the multisystem manifestations of mitochondrial diseases. We further discuss population-specific mitochondrial haplogroups and their reported population-specific associations with metabolic phenotypes, including obesity, type 2 diabetes (T2D), and cardiovascular disease (CVD). Finally, we review recent advances in next-generation sequencing technologies and their contributions to the molecular diagnosis of mitochondrial diseases and the characterization of genotype-phenotype relationships. Collectively, current evidence supports a well-established pathogenic role for specific mtDNA variants in primary mitochondrial disorders, whereas the contributions of common polymorphisms and haplogroups to complex metabolic disease remain largely associative and require further replication and functional validation.
    Keywords:  bioenergetics; heteroplasmy; metabolic disorders; mitochondrial disease; next-generation sequencing; oxidative phosphorylation
    DOI:  https://doi.org/10.3390/life16101590
  5. Genes (Basel). 2026 Oct 08. pii: 1236. [Epub ahead of print]17(10):
      Rare genetic diseases (RGDs) affect more than 300-400 million people worldwide [...].
    DOI:  https://doi.org/10.3390/genes17101236
  6. ArXiv. 2026 Oct 07. pii: arXiv:2610.09288v1. [Epub ahead of print]
      Many rare genetic diseases are associated with recognizable craniofacial features. However, traditional approaches for describing facial morphology rely largely on qualitative clinical observation and free-text descriptions, which are often subjective, non-standardized, and difficult to reproduce across observers and institutions. Although the Human Phenotype Ontology (HPO) provides controlled terms for describing facial features, these terms are typically categorical rather than quantitative and may vary depending on examiner experience and interpretation. Here, we present FaceKit, a computational framework for quantitative facial phenotyping from frontal facial photographs. FaceKit extracts standardized measurements of facial landmarks and derived 120 morphological features, then reports feature-level z-scores representing deviation from population reference distributions. The reference distributions are built from the FairFace dataset spanning diverse ancestral groups. We evaluated FaceKit on a curated subset of the GestaltMatcher Database covering 50 rare-disease cohorts. In addition to quantitative facial analysis, FaceKit includes synthetic facial image generation to support rare disease model development and data augmentation. We also performed privacy evaluation to assess whether synthetic images reveal identifiable information from real patient photographs and could compromise patient privacy. Across disease case studies, FaceKit-derived quantitative measurements captured known facial features associated with rare genetic disorders and provided objective support for clinical phenotyping. Together, these results establish FaceKit as a useful tool for quantitative phenotyping, and has the potential to improve rare disease diagnosis, support genotype-phenotype studies, and enable more reproducible clinical characterization across diverse patient populations.
    Keywords:  facial phenotyping; facial photo; landmarking; privacy evaluation; rare disease
  7. Orphanet J Rare Dis. 2026 Oct 30. pii: 382. [Epub ahead of print]21(1):
       BACKGROUND: A majority of the more than 6,500 rare diseases known today still lack specific therapeutic options. Low numbers of patients and consequently participants in clinical studies, as well as high costs of development in relation to return on investment have hindered pharmaceutical companies in the development of rare disease therapeutics. However, regulatory incentives and a number of international initiatives are promoting the orphan medicine market and clinical research on rare diseases to grow quickly. We collected data on clinical trials and observational studies for rare diseases in Austria for the decade between 2011 and 2021 using the Orphanet database. Our aim was to explore the development of clinical research on rare diseases during this pivotal decade with prominent advances in the field, using the Austrian data as an example for a small-to-medium-sized European country with a highly developed healthcare system.
    METHODS: We performed a systematic search in three large clinical study registers (the EU Clinical Trials Register, the ClinicalTrials.gov database of the National Institutes of Health, and the German Clinical Trials Register), entered the data in the Orphanet database and analysed them with regard to numbers, types of trials, rare diseases included, and medicinal products used.
    RESULTS: Our results show that the numbers of clinical trials on rare diseases have been rising steadily, with the most prominent fields being rare cancers, followed by rare autoimmune and autoinflammatory diseases. The most notable growth rates in therapeutic development strategies were seen for monoclonal antibodies, while small molecules, including the large group of kinase inhibitors, are the most frequently used products overall. Trials using advanced therapy medicinal products were still scarce in comparison.
    CONCLUSIONS: Taken together, clinical research in the rare disease field is increasing profoundly. While medicinal products targeting genetic diseases are still scarce, especially monoclonal antibodies are increasingly used in clinical trials on rare diseases, in addition to small molecule drugs. A profoundly different picture of clinical research on rare diseases and of the orphan medicine landscape can be expected in the following decade.
    Keywords:  ATMP; Advanced therapy medicinal products; Clinical research; Clinical study; Gene therapy; IRDiRC; International rare diseases research consortium; Orphan medicinal products; Orphan medicines
    DOI:  https://doi.org/10.1186/s13023-026-04673-z
  8. Exp Gerontol. 2026 Oct 29. pii: S0531-5565(26)00352-9. [Epub ahead of print] 113372
      Mitochondria arose from an alphaproteobacterial endosymbiont that became integrated within an archaeal host during eukaryogenesis. The discovery of Asgard archaea has clarified host ancestry and supports reconstructions in which aspects of cytoskeletal and membrane complexity preceded mitochondrial acquisition. Organellogenesis involved genome reduction, gene transfer, protein import, metabolic coupling, and vertical inheritance. These evolutionary principles complement current mitochondrial transplantation recommendations by generating testable predictions about recipient dependence and the duration of rescue. Transplanted mitochondria are mature organelles introduced into cells already equipped to maintain mitochondria; the requirement for transient or durable function must nevertheless be tested for each indication. Aging can modify organelle delivery, recipient quality control, and tissue responses, with particular implications for the neurovascular unit and neuronal function. Extracellular vesicle delivery requires verification of mitochondrial cargo, potency, and compatibility. Measurable criteria distinguish delivery, uptake, cytosolic access, network interaction, persistence, and functional benefit, while separating evidence from aging, acute ischemia, and inherited disease models.
    Keywords:  Asgard archaea; Endosymbiosis; Eukaryogenesis; Horizontal mitochondrial transfer; Mitochondrial transplantation; Organellogenesis
    DOI:  https://doi.org/10.1016/j.exger.2026.113372
  9. Drug Discov Today. 2026 Oct 28. pii: S1359-6446(26)00252-7. [Epub ahead of print] 104847
      European Union (EU) authorisation for the gene therapy medicinal product Waskyra® (etuvetidigene autotemcel; hereafter etu-cel) marks a milestone for patients living with Wiskott-Aldrich syndrome (WAS). The successful regulatory application for Waskyra by a non-profit organisation reflects not only the convincing scientific evidence supporting the authorisation, but also highlights that regulatory support is available from the European Medicines Agency (EMA) to help (small) developers manoeuvre the complexities of gene therapy medicinal product development for rare diseases. Here, we summarise the assessment by the EMA's Committees and present the key aspects underlying the positive outcome. Developers of innovative therapies addressing clear unmet medical needs are encouraged to seek early interaction with the EMA to help them design robust development programs and access supportive pathways that facilitate and accelerate development and evaluation.
    Keywords:  Wiskott–Aldrich syndrome; gene therapy medicinal product; medicines authorisation; regulatory Science; regulatory evaluation
    DOI:  https://doi.org/10.1016/j.drudis.2026.104847
  10. Pharmacol Res. 2026 Oct 27. pii: S1043-6618(26)01623-3. [Epub ahead of print]234 109708
      Mitochondrial dysfunction drives diseases, including ischemia-reperfusion injury, neurodegenerative disorders, cardiovascular disease, metabolic syndrome, and inflammation. Conventional mitochondria-targeted strategies offer only partial rescue and are insufficient for severe, irreversible damage. Mitochondrial transplantation (MT)-the delivery of exogenously isolated functional mitochondria to injured cells-has emerged as a promising therapeutic strategy that directly restores mitochondrial bioenergetic function and may subsequently modify the tissue microenvironment. This Review examines the entire MT pipeline, from mitochondrial source selection, isolation and preservation, to in vivo delivery strategies. We critically examine the multiple mechanisms underlying MT's therapeutic efficacy, including cellular uptake and intracellular integration, energy restoration and metabolic reprogramming, redox rebalancing, remodeling of mitochondrial quality control (fusion/fission, mitophagy, biogenesis), and immunomodulation. We summarize preclinical and clinical applications across multiple organ systems-heart, nervous system, liver, kidney, lung, skeletal muscle, retina-as well as in oncology and aging. We analyze five major translational bottlenecks: the lack of standardized manufacturing protocols, undefined dose-response relationships, immunogenicity and long-term safety uncertainties, the decisive impact of mitochondrial heterogeneity, and regulatory ambiguity. We outline future directions-mechanistic deepening, engineered target delivery, individualized mitochondrial medicine, combinatorial regimens, and a phased clinical roadmap. MT is not merely energy supplementation; it may reshape cellular metabolism, quality control networks, and immune microenvironments, representing a shift from pharmacological modulation of mitochondrial function toward organelle replacement strategies. Despite challenges, these advances may facilitate individualized mitochondrial therapies as a proposed future direction.
    Keywords:  Clinical translation; Individualized mitochondrial medicine; Metabolic reprogramming; Mitochondrial dysfunction; Mitochondrial quality control; Mitochondrial transplantation
    DOI:  https://doi.org/10.1016/j.phrs.2026.109708
  11. Int J Mol Sci. 2026 Oct 11. pii: 9010. [Epub ahead of print]27(20):
      Mitochondrial genomes (mitogenomes) are no longer considered entities solely responsible for cellular bioenergetics, but as dynamic, multifaceted, and synchronized systems that integrate genome architecture, evolutionary processes, and organismal physiology. The present review summarizes the contemporary understanding of mitogenome organization and its diversity, evolution, and associated functions across eukaryotic life, with emphasis on mitonuclear co-evolution and relevance to human health. Moreover, the conserved and lineage-specific characteristics of mitogenome architecture, including its genetic content, topology, and regulatory elements, and their roles in governing the precise replication and transcription of the mitogenome are also comprehensively discussed. Additionally, the review explores the role of evolutionary dynamics, with emphasis on mutation-rate heterogeneity, recombination dynamics, gene rearrangements, and the interaction between mutation, natural selection, and genetic drift in shaping mitochondrial genome diversity and evolutionary trajectories. Comparative approaches have revealed extensive diversity in mitogenome structural organization and composition, which are closely associated with life-history traits of organisms, including metabolic rate, longevity, and reproductive characteristics. Notably, at the functional level, the variability potential of a mitogenome significantly influences oxidative phosphorylation efficiency, reactive oxygen species generation, and the orchestration of cellular signaling cascades. Fundamental to these processes is the existence of coordinated mitonuclear interrelationships, wherein coevolution between mitochondrial and nuclear-encoded genes safeguards bioenergetic functional integrity, whereas disruptions in this coordination may lead to reduced cellular fitness and progression of several diseases. Particularly in humans, mutations in mitochondrial DNA (mtDNA) and heteroplasmy significantly contribute to the development of primary mitochondrial disorders and are increasingly implicated in other complex disease etiologies, including neurodegeneration, metabolic syndromes, and cancer. The paper also summarizes the phylogenetic utility of mitogenomes in the genomic era, accentuating the need to employ integrative approaches that combine mitochondrial and nuclear data. Lastly, the role of emerging technological platforms, including long-read sequencing and multi-omics, is also discussed, since these approaches are expected to transform the current landscape of mitogenome research. Altogether, the manuscript positions mitogenomes as indispensable entities bridging the gaps between evolutionary histories, physiological functions, and personalized precision medicine.
    Keywords:  Dn/Ds; PCGs; bioenergetics; heteroplasmy; mitochondrial DNA; mitochondrial disease; mitochondrial evolution; mitogenome architecture; mitogenomes; mitonuclear coevolution; mtDNA; nDNA; nuclear DNA; phylogenomics; protein-coding genes; substitution rates for non-synonymous and synonymous mutations (substitutions)
    DOI:  https://doi.org/10.3390/ijms27209010
  12. Cell Rep. 2026 Oct 29. pii: S2211-1247(26)01073-9. [Epub ahead of print]45(11): 117995
      Mitochondrial DNA (mtDNA) depletion and multiple deletions frequently coexist in mitochondrial disease, neurodegeneration, and aging, yet how the two relate and why deletions accumulate focally remain unresolved. Here, longitudinal bulk and in situ analyses of Mpv17-/- murine muscle reveal that a compensatory rise in mitochondrial transcripts per mtDNA initially offsets severe, uniform mtDNA depletion, preserving the respiratory chain. However, this response carries a delayed cost: by six months transcripts decline, mtDNA deletions emerge, and respiratory-deficient fibers appear. Paradoxically, fibers harboring deletions accumulate supra-physiological amounts of mtDNA, despite prior depletion. This expansion is invariably accompanied by elevated Hsp60, and the same holds in human mitochondrial myopathy. We propose that depletion reprograms mitochondrial DNA and RNA metabolism, inadvertently promoting deletion formation and creating an Hsp60-high fiber state permissive for clonal expansion. Therefore, depletion and multiple deletions can be sequential phases of a common degenerative process, relevant also to aging and neurodegeneration.
    Keywords:  CP: molecular biology; Hsp60; clonal expansion; mTORC1; mitochondrial DNA; mitochondrial DNA deletions; mitochondrial DNA depletion; mitochondrial myopathy; nanopore sequencing of mitochondrial DNA; single-fiber analysis; stress response
    DOI:  https://doi.org/10.1016/j.celrep.2026.117995
  13. Mol Neurobiol. 2026 Oct 30. pii: 1003. [Epub ahead of print]63(1):
      Acute central nervous system (CNS) injuries, including ischemic stroke, traumatic brain injury, and spinal cord injury, are characterized by profound mitochondrial dysfunction that drives secondary neuronal damage through ATP depletion, oxidative stress, and calcium dysregulation. Neuronal survival is critically dependent on mitochondrial integrity, making bioenergetic failure a central determinant of injury progression. In this context, intercellular mitochondria transfer has emerged as a potential adaptive mechanism through which functional mitochondria are delivered from donor cells-primarily astrocytes, microglia, and mesenchymal stem cells-to metabolically compromised neurons. Mitochondria transfer occurs via both contact-dependent pathways, such as tunneling nanotubes, and contact-independent mechanisms, including extracellular vesicles and free mitochondrial release. These processes are regulated by signaling pathways such as CD38/cADPR-mediated calcium flux and MIRO1-dependent mitochondrial trafficking, facilitating organelle mobilization and uptake. Functionally, transferred mitochondria have been associated with improved oxidative phosphorylation, reduced reactive oxygen species accumulation, altered calcium homeostasis, and modulation of survival pathways including PI3K/Akt and MAPK/ERK signaling in selected experimental models; however, the extent to which these effects are directly dependent on mitochondria transfer remains incompletely established. Preclinical evidence across multiple CNS injury models demonstrates improved neuronal viability, enhanced synaptic function, and attenuation of neurodegenerative processes following mitochondria transfer. However, whether mitochondria transfer represents a primary driver of neurorepair or a secondary compensatory response remains unresolved. In addition, inconsistencies in mechanistic pathways, variability in transfer efficiency, and limited reproducibility across experimental systems hinder translational interpretation. Therapeutic approaches including exogenous mitochondria transplantation, stem cell-mediated delivery, and bioengineered mitochondrial systems show promise but face substantial barriers related to targeting specificity, mitochondrial viability, immunogenicity, and lack of standardized protocols. This review critically evaluates the molecular mechanisms, functional consequences, and therapeutic potential of intercellular mitochondria transfer in CNS injury. It further highlights key limitations and knowledge gaps that must be addressed to determine whether mitochondria transfer can be effectively harnessed as a clinically viable strategy for neuro-restoration.
    Keywords:  Central nervous system injury; Intercellular mitochondria transfer; Mitochondrial dysfunction; Neuronal bioenergetics; Neuroprotection
    DOI:  https://doi.org/10.1007/s12035-026-06303-y
  14. Med Rev (2021). 2026 Oct;6(5): 444-448
      Pluripotent-state transitions are accompanied by coordinated changes in mitochondrial architecture, signaling, metabolism, and turnover, yet whether these changes drive, follow, or reciprocally interact with cell-state transitions remains incompletely resolved. Here, we evaluate evidence across three mitochondrial routes: architecture and positioning, mitochondria-to-nucleus communication, and mitochondrial quality control. Direct perturbation and rescue studies show that selected mitochondrial processes can promote or restrain pluripotency acquisition and transitions between pluripotent states. However, their effects depend on transition identity and phase, perturbation timing, duration and magnitude, species, and culture context. We therefore propose that mitochondrial processes should be considered instructive only when they bias a defined pluripotent-state transition through a state-relevant mechanism rather than simply altering cellular fitness or state stability.
    Keywords:  epigenetic regulation; mitochondria; mitochondrial retrograde signaling; mitophagy; pluripotent-state transitions; somatic cell reprogramming
    DOI:  https://doi.org/10.1515/mr-2026-0047
  15. Genes (Basel). 2026 Sep 22. pii: 1161. [Epub ahead of print]17(10):
       BACKGROUND: Large-scale mitochondrial DNA (mtDNA) rearrangement, including deletion or duplication, is one of the important causes of primary mitochondrial disease. In clinical practice, short-read sequencing (SRS)-based assays typically detect these rearrangements by identifying regional mtDNA copy-number changes but generally do not directly distinguish deletions from duplications. As a result, mtDNA duplications may be misclassified as deletions, potentially leading to inaccurate molecular diagnoses and genotype-phenotype correlations. This study aimed to evaluate the utility of long-read sequencing (LRS) for the definitive characterization of large-scale mtDNA rearrangements.
    METHODS: Two individuals who had been reported to possess single large-scale mtDNA deletions using SRS-based clinical tests were re-evaluated because their clinical presentations were not consistent with typical mtDNA deletion syndromes. Existing SRS data were reanalyzed, and the suspected rearrangements were independently characterized using both Pacific Biosciences (PacBio) and Oxford Nanopore Technologies long-read sequencing platforms.
    RESULTS: Reanalysis of SRS data suggested that the reported deletions were more consistent with mtDNA duplications. This finding was confirmed by both PacBio and Oxford Nanopore LRS in one case. Reclassifying the deletion to a duplication in this case substantially improved genotype-phenotype interpretation and better explained the atypical clinical features observed in this individual. However, LRS could not capture sufficient long reads that give direct evidence of duplication in the second case due to low heteroplasmy of the mtDNA structural variant. Therefore, this case remains inconclusive.
    CONCLUSIONS: SRS and LRS provide complementary information for the evaluation of large-scale mtDNA rearrangements. SRS can sensitively identify mtDNA large deletions, but it cannot distinguish mtDNA deletion from duplication. On the other hand, LRS can provide direct structural information and confirm duplication. However, LRS may have limited sensitivity for low-level heteroplasmic structural variants. An integrated approach incorporating both methods, together with clinical correlation and reanalysis of potentially discordant findings, may improve the characterization and interpretation of mtDNA rearrangements.
    Keywords:  Illumina short-read sequencing; Oxford Nanopore Technologies long-read sequencing; PacBio long-read sequencing; mitochondrial DNA (mtDNA); mtDNA deletions and duplications
    DOI:  https://doi.org/10.3390/genes17101161
  16. J Dev Biol. 2026 Oct 19. pii: 45. [Epub ahead of print]14(4):
      The 2026 Barth Syndrome International Scientific, Medical & Family Conference was held at the Hyatt Regency Coconut Point, Bonita Springs, Florida, USA, from 19th to 25th July 2026 with scientific programming beginning 22nd July. This biennial event assembled researchers, clinicians, and affected community members for its first gathering since the U.S. FDA granted accelerated approval to elamipretide (Forzinity™; Mighty Therapeutics), the first therapy for Barth syndrome and first ever mitochondrially targeted therapy, in September 2025. Scientific sessions addressed: (1) emerging cardiolipin biology; (2) convergent identification of ABHD18 as a therapeutic target for correction of the cardiolipin phenotype; (3) advancing therapeutic strategies including AAV gene therapy, enzyme replacement therapy, and ABHD18 inhibition; (4) the elamipretide post-approval program, including the SPIBA-401 confirmatory trial; (5) natural history characterization covering infant outcomes, extra-cardiac manifestations, diaphragm weakness, neutropenia, and amino acid metabolism; (6) regulatory and drug development strategies in ultra-rare indications; and (7) international Centers of Expertise models and the launch of the BarthINSIGHTS registry. This report summarizes the key scientific advances, discussions, and future priorities as they relate to Barth syndrome biology, therapeutic development, and clinical care.
    Keywords:  ABHD18; Barth syndrome; Centers of Expertise; TAFAZZIN; cardiolipin; elamipretide; enzyme replacement therapy; gene therapy; mitochondrial disease; natural history; ultra-rare disease drug development
    DOI:  https://doi.org/10.3390/jdb14040045
  17. Front Aging. 2026 ;7 1920914
      Mitochondrial function is essential for brain health. Its age-related decline impairs neuronal resilience and increases risk for the development of neurodegenerative diseases. As sex is an important biological variable in both physiological and pathological brain function, in this mini review, we highlight emerging evidence of sex differences in mitochondrial content and function in the brain and what is currently understood about how they change with age. Furthermore, as physical exercise is considered a key mitigating factor in brain injury and the development of neurodegenerative diseases, we review studies that address the effects of exercise on mitochondrial function in the brain, with particular attention to those that include data from both sexes. The current understanding of the effects of sex differences and exercise on brain mitochondrial function over the lifespan is limited, but nonetheless some interesting insights are emerging. We discuss the key knowledge gaps and offer some suggestions for further research. These include defining the extent and specificity of mitochondrial alterations with age in different species, brain regions and cell types, and their modification by exercise, which is both important for advancing aging biology and for designing intervention strategies to promote healthy aging, to mitigate age-dependent cognitive decline and treat neurodegenerative diseases.
    Keywords:  age; brain; exercise; mitochondria; sex
    DOI:  https://doi.org/10.3389/fragi.2026.1920914
  18. Nat Metab. 2026 Oct 27.
      Mutations in mitochondrial DNA (mtDNA) impair ETC activity and oxidative phosphorylation, but their phenotypic consequences vary with heteroplasmy levels. Whether increasing mtDNA heteroplasmy creates metabolic dependencies not present in respiratory-competent cells remains unknown. Here, we show that low pyruvate carboxylase (PC) expression creates an asparagine dependency in high-mtDNA-heteroplasmy, respiration-compromised cells. In isogenic cells carrying similar mtDNA deletions, respiration declines linearly with increasing heteroplasmy, whereas redox imbalance emerges only above 50% heteroplasmy. Above 70% heteroplasmy, integrated stress-response-associated translational defects emerge, which can be reversed by either exogenous asparagine or PC overexpression. Asparagine dependence inversely correlates with PC expression across respiration-deficient cells. Consistent with this pattern, patient-derived thyroid tumour cells harbouring a high-heteroplasmy complex I mutation and low PC levels exhibit asparagine auxotrophy and sensitivity to L-asparaginase. Together, these findings demonstrate a role for mitochondrial PC in cellular asparagine synthesis under conditions of compromised respiratory activity.
    DOI:  https://doi.org/10.1038/s42255-026-01651-4
  19. Nat Commun. 2026 09 24. pii: 11098. [Epub ahead of print]17(1):
      The ClpXP ATP-dependent unfoldase-protease complex plays important roles in maintaining protein homeostasis in the mitochondria. Pathogenic variants of CLPP have been identified in patients with Perrault syndrome type 3 (PRLTS3), a rare recessive mitochondrial disease characterized by sensorineural hearing loss, ovarian dysfunction, and neurological abnormalities. However, it remains unclear how these ClpP variants cause this disease. Here we identify three cellular substrates of ClpXP using proteomic analysis of PRLTS3 patient-derived fibroblasts, with follow up studies using induced pluripotent stem cells (iPSCs) and iPSC-derived neural progenitor cells, alongside in vitro biochemical assays. These substrates are: CHCHD2, a bi-organellar regulator of oxidative phosphorylation and mitochondrial stress responses; ALAS1, which catalyzes the rate-limiting step in heme biosynthesis; and TFAM, an essential mitochondrial transcription factor. Efficient degradation of these substrates by ClpXP requires the adaptor protein PDIP38. We propose that dysregulated cellular levels of these substrates might contribute to the etiology of PRLTS3.
    DOI:  https://doi.org/10.1038/s41467-026-77888-0
  20. J Drug Target. 2026 Oct 29. 1-45
      Parkinson's disease is the second most widely diagnosed neurodegenerative disorder in the world, affecting more than 10 million people, with current drug therapies for treatment providing limited symptomatic relief and no effect on stopping disease progression. The integration of AI and Pharmaceutical Sciences has led to a change in the approach to discovering and developing new anti-Parkinsonian drugs. This review presents a comprehensive overview of the many applications of Machine Learning (ML), Deep Learning (DL), Graph Neural Networks (GNNs) and Generative AI to the PD drug development process.We have critically examined AI-guided target identification, including disruption of α-synuclein (SNCA) fibrils, inhibition of Leucine Rich Repeat Kinase 2 (LRRK2), modulation of GBA1/Glucocerebrosidase and restoration of mitochondrial functions via PINK1/Parkin along with the application of Transformer-based models such as AlphaFold2 and RoseTTAFold to elucidate the structures of Pathological proteins and create the basis for conducting AI-accelerated Virtual Screening studies, yielding exciting lead compounds.Although tremendous advancements have been made, many obstacles need to be overcome, such as obtaining rare disease data, improving the interpretability of the data used in AI models, developing appropriate regulatory pathways, and bridging the gap between pre-clinical and clinical data.
    Keywords:  LRRK2; Parkinson's disease; alpha-synuclein; artificial intelligence; blood–brain barrier; drug delivery; generative AI; machine learning; nanoparticles; virtual screening
    DOI:  https://doi.org/10.1080/1061186X.2026.2756474
  21. J Neurochem. 2026 Oct;pii: e70561. [Epub ahead of print]170(10):
      PINK1 and Parkin regulate mitochondrial quality control in both neuronal and immune-cell populations, but their roles during autoimmune neuroinflammation in aging remain incompletely understood. We investigated the association of PINK1 or Parkin deficiency with clinical disease, peripheral immune responses, CNS inflammation, and neuronal mitochondrial morphology during experimental autoimmune encephalomyelitis (EAE). EAE was induced in aged PINK1-/- and PARK2-/- mice and age-matched controls. Clinical disease was assessed longitudinally, while independent cohorts were analyzed at peak disease using flow cytometry, spinal cord histology, transmission electron microscopy, and Western blotting of mitochondrial fractions. PINK1-/- and PARK2-/- showed greater cumulative disease burden and incomplete clinical recovery, most prominently in PARK2-/- mice. At peak disease, knockout mice exhibited increased dendritic cells, monocytes, and CD8+ T cells, while aged knockouts showed more IFN-γ-producing CD4+ and CD8+ T cells following ex vivo stimulation. Increased spinal cord inflammation was not accompanied by genotype-dependent differences in myelin staining. Ultrastructural analysis revealed more numerous, smaller mitochondria in substantia nigra pars compacta and motor cortex neurons, accompanied by selective alterations in OPA1 and DRP1, but not MFN2. These findings demonstrate that PINK1 or Parkin deficiency is associated with enhanced inflammation, greater EAE disease burden, and altered neuronal mitochondrial morphology in aging. These results support an association between immune dysregulation and altered mitochondrial homeostasis without establishing impaired mitophagy or a direct causal relationship.
    Keywords:  EAE; PARKIN; PINK1; aging; mitochondrial fragmentation; mitophagy; neuroinflammation; substantia nigra
    DOI:  https://doi.org/10.1111/jnc.70561
  22. Eur J Clin Invest. 2026 Nov;pii: e70269. [Epub ahead of print]56(11):
       BACKGROUND: Mitochondrial dysfunction is increasingly implicated in coronary artery disease (CAD), but the relationship between mitochondrial DNA copy number (mtDNA-CN) and mitochondrial homeostasis across CAD presentations remains unclear. We investigated mtDNA-CN together with the expression of key regulators of mitochondrial biogenesis (PGC-1α and TFAM) and mitophagy (PINK1) in patients with stable angina (SA) and acute coronary syndrome (ACS).
    METHODS: This observational study included 334 patients: 170 ACS, 117 SA and 47 individuals with non-obstructive coronary arteries (NCA). Peripheral blood mtDNA-CN and the expression of PGC-1α, TFAM and PINK1 were quantified by real-time PCR. Associations with clinical characteristics, inflammatory markers and left ventricular ejection fraction (LVEF) were evaluated.
    RESULTS: ACS patients exhibited significantly lower mtDNA-CN than SA and NCA groups (p = 0.01 and p = 0.004, respectively). PINK1 expression was reduced in both ACS (p = 0.005) and SA (p = 0.01) compared with NCA. TFAM expression was increased in SA (p = 0.009), while PGC-1α expression was higher in ACS (p = 0.02). MtDNA-CN and mitochondrial biomarkers were inversely associated with inflammatory markers, whereas mtDNA-CN and TFAM correlated positively with LVEF. Lower mtDNA-CN was independently associated with ACS (OR = 0.98, p = 0.0004) and SA (OR = 0.99, p = 0.04), while higher PINK1 expression was associated with reduced odds of SA (p = 0.03) and ACS (p = 0.02).
    CONCLUSIONS: Mitochondrial markers are altered across CAD phenotypes. ACS is characterized by lower mtDNA-CN and altered expression of mitochondrial homeostasis-related genes, whereas SA shows a pattern consistent with a possible compensatory response. Combined assessment of mtDNA-CN and mitochondrial homeostasis-related gene expression may provide a novel biomarker strategy for CAD risk stratification and targeted therapies.
    TRIAL REGISTRATION: VICTORIA study, (ClinicalTrials.gov Identifier: NCT06313645).
    Keywords:  acute coronary syndrome; coronary artery disease; mitochondrial DNA copy number; mitochondrial biogenesis; mitochondrial homeostasis; mitophagy
    DOI:  https://doi.org/10.1111/eci.70269
  23. Cell Rep. 2026 Oct 29. pii: S2211-1247(26)01217-9. [Epub ahead of print]45(11): 118138
      Daniali et al. show that dopamine drives mitochondrial stress, mtDNA release, and cGAS-STING-dependent IL-6 production in human macrophages. These findings suggest a mechanism linking dopaminergic signaling to mtDNA damage signatures increasingly detected in blood from patients with Parkinson's disease.
    DOI:  https://doi.org/10.1016/j.celrep.2026.118138
  24. bioRxiv. 2026 Oct 09. pii: 2026.10.08.757705. [Epub ahead of print]
      Mitochondrial DNA (mtDNA) mutations cause inherited disease, accumulate with age, and recur in tumors, yet their effects remain unresolved because existing models interrogate one engineered allele at a time. We developed mtDIVE, a random C→T mutagenesis platform for pooled mitochondrial forward genetics in human epithelial cells and zebrafish embryos. mtDIVE generates genotypes ranging from single substitutions to >100 mutations per molecule, impairs respiration, and causes lineage-specific developmental delay. Coupling single-cell transcriptomics with mtDNA genotyping revealed that selection on mutant genomes and their transcriptional consequences depend on metabolic state and developmental lineage. Obligate OXPHOS eliminates highly mutated cells by apoptosis, whereas glycolytic conditions promote their competitive displacement. Individual loci exert modest but non-redundant effects that predict cell state beyond aggregate mutation burden, and cancer-recurrent variants are enriched among mutations linked to reduced mitochondrial transcription. Thus, mtDIVE links mtDNA genotypes to cellular phenotypes, separating the consequences of mutation identity from mutational load.
    DOI:  https://doi.org/10.64898/2026.10.08.757705
  25. Pediatr Phys Ther. 2026 Oct 23.
       PURPOSE: Children with neurodisabilities, including cerebral palsy and rare diseases, often experience significant mobility limitations. Locomotor training, including a combination of partial body weight-supported treadmill training and overground walking in a supported stepping device, may support functional development. This study evaluated the feasibility of a 6-week locomotor training program for young children with neurodisabilities and significant motor impairments.
    METHODS: A single-group pre-post study included 71 children (mean age = 2.8 years). Feasibility was assessed using Bowen's framework across 4 domains: limited efficacy testing, practicality, acceptability, and adaptability. Outcome measures included Goal Attainment Scaling, Canadian Occupational Performance Measure, 10-m walk test, and 6-minute walk test.
    RESULTS: All outcome measures improved. Goal Attainment Scaling scores increased from 12.8 to 56.2, with 85% achieving goals. Canadian Occupational Performance Measure and mobility outcome measures exceeded clinically meaningful thresholds. The program was well-tolerated (mean therapy hours = 14.1), was adaptable across a heterogeneous cohort, and there were no major adverse events.
    CONCLUSIONS: Locomotor training involving partial body weight-supported treadmill training and overground walking in supported stepping devices is feasible and beneficial for young children with neurodisabilities and significant motor impairments. Further studies are warranted to explore long-term efficacy and generalizability.
    Keywords:  cerebral palsy; feasibility; locomotor training; mobility training; neurodisability; partial body weight supported treadmill training; pediatric physiotherapy; rare disease; supported stepping device
    DOI:  https://doi.org/10.1097/PEP.0000000000001319
  26. Lab Med. 2026 Oct 05. pii: lmag081. [Epub ahead of print]57(6):
       INTRODUCTION: Clinical exome sequencing (ES), commonly referred to as whole-exome sequencing (WES), is widely used to diagnose suspected Mendelian and rare diseases. However, many patients remain undiagnosed after initial analysis. A negative or non-diagnostic result does not necessarily exclude a genetic etiology, as genomic knowledge and patient phenotypes evolve over time. This review examines post-test strategies for extending the clinical utility of ES.
    METHODS: We conducted a narrative review of the literature identified through PubMed/MEDLINE, Web of Science Core Collection, and Google Scholar, with searches performed on August 5, 2026. The review synthesized evidence and practical considerations concerning exome reanalysis, variant reclassification, dynamic reporting, and complementary diagnostic approaches.
    RESULTS: Non-diagnostic ES results may reflect technical and bioinformatics limitations, incomplete clinical or family information, evolving gene-disease knowledge, uncertain variant evidence, or genetic mechanisms beyond the detection scope of conventional ES. Structured reanalysis incorporating updated phenotype information, databases, analytical methods, and family evidence may identify additional diagnoses. Variant reclassification and dynamic report updating support longitudinal interpretation, while secondary findings and artificial intelligence-assisted workflows require appropriate oversight. When reanalysis is insufficient, mechanism-guided escalation to genome sequencing, RNA sequencing, long-read sequencing, methylation testing, biochemical testing, or functional assays may be appropriate.
    DISCUSSION: Structured reanalysis and dynamic reporting can transform ES from a one-time molecular test into a longitudinal diagnostic process. Their implementation requires transparent reanalysis criteria, traceable interpretation, appropriate communication of uncertainty, and sustainable laboratory workflows to support clinical decision-making and precision medicine.
    Keywords:  VUS; clinical utility; dynamic reporting; exome sequencing; genomic diagnosis; molecular diagnosis; precision medicine; rare disease; reanalysis; variant reclassification
    DOI:  https://doi.org/10.1093/labmed/lmag081
  27. Intern Med J. 2026 Nov;56 Suppl 5 6
      Genetic and genomic testing can refine diagnosis, prognosis, treatment, transplant assessment and family counselling for kidney disease, yet access remains uneven across Australia. These National Kidney Genomics Guidelines define a standard of care for genetic and genomic testing in nephrology and support the mainstreaming of genomic care while maintaining quality, governance and equity. The guidelines were developed by the KidGen Collaborative, comprising nephrologists, clinical geneticists, genetic counsellors, diagnostic laboratories, scientists and consumer advocates, including Aboriginal and Torres Strait Islander representatives. They underwent open review. Recommendations are graded by strength and by the quality of evidence. The document covers governance and multidisciplinary models; patient selection and phenotyping; clinical indications, including transplantation; test selection; consent; requesting and funding; interpretation of results; post-test management and re-analysis; familial variant testing; and patient and clinician support. Equitable access for rural and remote communities, culturally and linguistically diverse groups, and Aboriginal and Torres Strait Islander peoples is prioritised. Predictive testing of asymptomatic relatives and testing of children without immediate medical benefit should be conducted through specialised genetics services. Variants of uncertain significance should not guide management. The guidelines are intended for nephrologists, clinical geneticists, genetic counsellors and health-service decision-makers, and will be reviewed every three to five years, or sooner if practice-changing evidence emerges.
    DOI:  https://doi.org/10.1111/imj.70703
  28. Science. 2026 Oct 29. 394(6823): eaed2525
      Targeted protein degradation is a promising modality to treat cancer or inflammation, but whether it can provide a similar benefit for disorders caused by pervasive protein dysregulation is unclear. We describe stimulated protein degradation (SPD) as a strategy that leverages agonists of stress-responsive E3 ubiquitin ligases to simultaneously eliminate multiple pathogenic factors. Specifically, we show that activators of the reductive stress response E3 CUL2FEM1B boost degradation of multiple physiological substrates to improve mitochondrial import and electron transport chain assembly. In this manner, CUL2FEM1B agonists preserve mitochondrial function and neuronal survival in models of neurodegenerative COX deficiency syndrome and Friedreich's ataxia. By activating E3 ligases that evolved to safeguard cellular integrity, SPD expands the use of compound-induced protein degradation to complex pathologies of high unmet need.
    DOI:  https://doi.org/10.1126/science.aed2525
  29. NEJM AI. 2026 Jul;3(7): AIp2501235
      AbstractEnd point evaluation is central to the evidence generation process in a clinical trial, and artificial intelligence (AI) tools have the potential to improve the efficiency and accuracy of this process. In 2025, the European Medicines Agency and U.S. Food and Drug Administration independently endorsed AIM-NASH, an AI-based tool for histologic assessment in clinical trials for metabolic dysfunction-associated steatohepatitis. As the first ever regulatory certification of an AI-enabled end point, this represents a milestone for the emerging development and use of AI tools for drug development. This article examines the evidence and policy decisions underlying the endorsement and explores the clinical and regulatory implications of AI-enabled end points for the transformation of clinical trials.
    DOI:  https://doi.org/10.1056/AIp2501235
  30. Integr Zool. 2026 Oct 24.
      Public mitochondrial genome records vary considerably in annotation quality and nomenclature, complicating comparative analyses of gene content and gene order. We developed MitoOmicsDB, a web-based platform for the standardized curation, retrieval, visualization, and analysis of metazoan mitochondrial genomes. Its NCBI2GO pipeline normalizes gene names, strand orientation, coordinate origins, transfer RNA identities, and other annotation features, while retaining unresolved cases for manual examination. Source annotations, automated results, and subsequent manual corrections remain linked to their original accessions to support review and reuse. The current source dataset contains 61 778 metazoan mitochondrial genome records, although taxonomic representation and the extent of curation remain uneven. The systematically processed vertebrate subset includes 7317 complete reference genomes from five major groups and represents 694 distinct gene order types. Users can search and download processed records, visualize mitochondrial gene arrangements, and upload GenBank files for annotation cleaning. The resulting data can be exported for downstream gene order analyses. By combining automated normalization with taxon-informed manual curation, MitoOmicsDB provides a shared framework for improving annotation consistency and facilitating broad comparative studies of mitochondrial genome organization across Metazoa.
    Keywords:  Metazoa; comparative genomics; gene order; mitochondrial genome; web database
    DOI:  https://doi.org/10.1111/1749-4877.70228